Paper Details

  1. Home
  2. Paper Details

Week 96 efficacy and safety of rilpivirine in treatment-naive, HIV-1 patients in two Phase III randomized trials.

Author: , BovenKatia, CassettiIsabel, ChetchotisakdPloenchan, CohenCalvin J, CrauwelsHerta, LazzarinAdriano, LiTaisheng, MolinaJean-Michel, OrkinChloe, RhameFrank, RimskyLaurence, StellbrinkHans-Jürgen, VanveggelSimon, WilliamsPeter

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

This pooled 96-week analysis of two randomized, double-blind, double-dummy Phase III trials compared rilpivirine to efavirenz for treatment-naive, HIV-1-infected adults. Both treatments had comparable responses at week 96, with rilpivirine having more virologic failures but improved tolerability.
Paper Details　
Original Abstract of the Article :
BACKGROUND: In the week 48 primary analysis of ECHO and THRIVE, rilpivirine demonstrated noninferior efficacy and more favourable tolerability versus efavirenz in treatment-naive, HIV-1-infected adults. Pooled 96-week results are presented. METHODS: Patients (N = 1368) received rilpivirine 25 mg on...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1097/QAD.0b013e32835cee6e

データ提供：米国国立医学図書館（NLM）

Rilpivirine: A Long-Term Solution for HIV-1 Treatment?

The fight against HIV-1 is a relentless journey across a vast and unforgiving desert. This study investigates the long-term efficacy and safety of rilpivirine, a medication used to treat HIV-1 infection, in treatment-naive patients. The authors analyzed data from two Phase III randomized trials, comparing rilpivirine to efavirenz, another commonly used HIV-1 medication, over a 96-week period. Their results indicate that rilpivirine and efavirenz had comparable efficacy in suppressing viral load, but rilpivirine exhibited a more favorable safety profile with a lower incidence of adverse events, particularly during the second year of treatment.

Long-Term Efficacy and Safety of Rilpivirine for HIV-1 Treatment

This study provides long-term evidence for the efficacy and safety of rilpivirine in treating HIV-1 infection. The comparable efficacy with a more favorable safety profile suggests that rilpivirine could be a valuable treatment option for patients seeking a long-term solution for managing HIV-1. The study's findings encourage further research into the long-term benefits and potential of rilpivirine in HIV-1 treatment.

Navigating the Desert of HIV-1 Treatment: A Promising Oases

The journey of HIV-1 treatment can be as arduous as a camel trek across a scorching desert. This study highlights rilpivirine as a promising oasis, offering a more tolerable and long-term solution for managing the virus. The findings suggest that rilpivirine can effectively suppress viral load while minimizing side effects, providing a more manageable and hopeful path for individuals living with HIV-1.

Dr. Camel's Conclusion

This study provides valuable insights into the long-term efficacy and safety of rilpivirine in treating HIV-1. The results suggest that rilpivirine offers a comparable level of efficacy to other commonly used medications, but with a more favorable safety profile. This research contributes to a growing understanding of rilpivirine's potential as a long-term treatment option for HIV-1, offering hope for individuals seeking a more manageable and effective path to managing the virus.

Date :
  1. Date Completed 2013-10-24
  2. Date Revised 2022-04-09
Further Info :

Pubmed ID

23211772

DOI: Digital Object Identifier

10.1097/QAD.0b013e32835cee6e

Related Literature

Article Analysis
・Side Effects of rilpivirine
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.